The Danish pharmaceutical giant on Monday said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop 15.7% of their weight after 68 weeks.

which is “what we expected in this data scenario,” as CagriSema weight loss data is not as differentiated compared to Eli Lilly’s (LLY) Zepbound as was expected. Weight loss in the REDEFINE ...

Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight ...

SAN DIEGO — Coadministration of the long-acting amylin analog cagrilintide plus the glucagon-like peptide-1 (GLP-1) agonist semaglutide, dubbed CagriSema, resulted in significantly greater ...

Novo Nordisk (NVO) plunged to a 52-week low on Friday after the Danish drugmaker released Phase 3 results for its next-gen weight loss therapy, CagriSema, as data gave a pause for its investors ...

Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News. In a new study, an ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

CagriSema is designed by combining semaglutide, the active ingredient of Novo’s (NVO) popular weight loss therapy, Wegovy, with another compound mimicking a metabolic hormone called amylin.

Novo's late-stage trial testing CagriSema is the most advanced of its pipeline of potential drugs and investors say currently the most significant because Novo said it expects the weekly injection ...

Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...